📣 Send us your press release
Site updates every 15 minutes
Health

US regulators approve AstraZeneca's Klygefa for myasthenia gravis

The FDA has granted approval to Klygefa for the treatment of generalized myasthenia gravis in adult patients.

16 November 2026

AstraZeneca’s rare disease division, Alexion, has received US regulatory approval for Klygefa (gefurulimab) to treat generalized myasthenia gravis (gMG) in adults. The drug serves as a new therapeutic option for individuals suffering from the chronic autoimmune condition.

The approval follows positive outcomes from the Phase III PREVAIL trial, which demonstrated that patients experienced significant improvements in daily functioning beginning within the first week of treatment. These improvements remained consistent throughout a 52-week study period.

Klygefa is the first dual-binding nanobody C5 inhibitor to be approved by the FDA for this indication. Designed for weekly subcutaneous self-administration, the treatment aims to provide patients with greater flexibility in managing disease symptoms compared to traditional infusions.

Original source: news.cision.com